Posted: March 1, 2024 at 2:45 am
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes
Follow this link:
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Posted: March 1, 2024 at 2:45 am
- Phase 2 trial in patients with RAS-mutated mCRC will evaluate onvansertib plus SoC versus SoC alone in the first-line setting -
Read this article:
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
Posted: March 1, 2024 at 2:45 am
WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays Global Healthcare Conference in Miami, March 12-14, 2024.
Read more:
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
Posted: March 1, 2024 at 2:45 am
Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data
More:
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
Posted: March 1, 2024 at 2:45 am
- New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients -
See the rest here:
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
Posted: March 1, 2024 at 2:45 am
- First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite -
Read this article:
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Posted: March 1, 2024 at 2:45 am
Provides Full Year 2024 Financial Guidance Provides Full Year 2024 Financial Guidance
View post:
Certara Reports Fourth Quarter 2023 Financial Results
Posted: March 1, 2024 at 2:45 am
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of December 31, 2023 and revenues for 2023.
Visit link:
GENFIT Announces Revenues and Cash Position as of December 31, 2023
Posted: March 1, 2024 at 2:45 am
EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that Brian C. Thomas, CEO & Founder, will participate in a panel titled, “Emerging Genetic Therapy Approaches,” during the 44th Annual Cowen Healthcare Conference on Wednesday, March 6, 2024 from 12:50-1:50 PM ET in Boston.
See the original post:
Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference
Posted: March 1, 2024 at 2:45 am
SOUTH ORANGE, NJ, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its fourth quarter and fiscal year financial results on Thursday March 7, 2024 after market close and will host a conference call that same day at 4:30pm ET.
Read the original:
Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results
